trending Market Intelligence /marketintelligence/en/news-insights/trending/bhqiiww_ol0qvqbmljxpww2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Progenics, Par Pharma settle patent dispute over Relistor injection

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Progenics, Par Pharma settle patent dispute over Relistor injection

Progenics Pharmaceuticals Inc. settled a lawsuit against Par Pharmaceutical Inc., which is seeking to market a copycat version of the company's Relistor injection in the U.S.

Progenics and its partners Valeant Pharmaceuticals International Inc., Salix Pharmaceuticals Inc. and Pfizer Inc.'s Wyeth LLC, had said Par's generic methylnaltrexone bromide injection would infringe on two of their patents covering Relistor, a treatment for opioid-induced constipation.

The companies had filed a lawsuit against Par, which is owned by Endo International PLC, in the U.S. District Court for the District of New Jersey.

The settlement terminates the 30-month stay imposed by the U.S. Food and Drug Administration in relation to the approval of Par Pharmaceutical's abbreviated new drug application and allows it to market a generic version of the injection starting Sept. 30, 2030, or earlier under certain circumstances.